To recover your password please fill in your email address
Please fill in below form to create an account with us
SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
|
Trial Summary: |
To assess the activity and tolerability of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar in non-squamous metastatic NSCLC with KRAS G12C mutation. |
|
Supported By: |
AMGEN |
|
Eligibility: |
Participants with histologically confirmed non-squamous NSCLC with KRAS G12C mutation, with either treatment naïve newly diagnosed metastatic (Stage IV) cancer, or recurrent disease with no progression for at least 6 months following prior curative therapy |
|
Registration ID: |
ACTRN12622000973718 |
|
Participation: |
Australia |
|
Australian Lead Group: |
TOGA |
|
Status: |
Recruiting |
|
Activation Date: |
24th August 2022 |
|
Chairs: |
A/Prof Chee Lee |
|
Contact: |